NSE: GLENMARK | BSE: 532296

Mid-range Performer

Download real time

2173.80 29.30 (1.37%)

35.44% Gain from 52W Low

514.8K NSE+BSE Volume

NSE 12 Jun, 2026 3:31 PM (IST)

61,344.8

Market Cap

High in industry

Beta 1Year

Very Low volatility

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Search Inside the pdf :

Glenmark Pharmaceuticals Ltd.

10 Jun 2026

2173.80

1.37%

Innovation Business Can Become a Major Value Driver

Accumulate: Glenmark Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

Outlook remains positive, supported by multiple growth drivers across its innovation, specialty, and US generics businesses. Continued scaling of Ryaltris, commercialization of new respiratory products in the US, and the restart of injectable operations are expected to support earnings growth over the next few years.

Glenmark Pharmaceuticals Ltd. is trading below its 30 day SMA of 2292.1

Glenmark Pharmaceuticals Ltd.

01 Jun 2026

2173.80

1.37%

A mixed quarter; US/DF underperforms for the quarter

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) delivered lower-than-expected financial performance for the quarter. While revenue was in line with our estimate, EBITDA was a 7% miss.

Glenmark Pharmaceuticals Ltd.'s price crossed above 100Day SMA today

Glenmark Pharmaceuticals Ltd.

03 Feb 2026

2173.80

1.37%

Sustainability of cost curbs key to boost earnings growth

Sell: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Glenmark’s Q3FY26 revenue growth was led by India biz, while US growth was muted post adjusted for USD 18mn of milestone income. Gross margin was lower by 259bps YoY due to unfavourable product and geographical mix, though cost curbs drove 131bps expansion in EBITDA margin.

Number of FII/FPI investors increased from 422 to 436 in Mar 2026 qtr.

Glenmark Pharmaceuticals Ltd.

02 Feb 2026

2173.80

1.37%

Mixed quarter; domestic strengthens

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) posted largely in-line financial performance in 3QFY26. The quarterly performance was driven by a healthy revival in the domestic formulation (DF) business, out-licensing income related to ISB2001, and better performance in emerging markets.

Glenmark Pharmaceuticals Ltd.'s price crossed above 100Day SMA today

Glenmark Pharmaceuticals Ltd.

18 Nov 2025

2173.80

1.37%

Exceptional Q2 buoyed by ISB-2001 income and sharp margin expansion.

Buy: Glenmark Pharmaceuticals Ltd.

Deven Choksey

We have rolled forward our valuation to Sept’27 estimates. We value Glenmark Pharma at 25.0x Sept’27 EPS implying a target price of INR 2,300.

Glenmark Pharmaceuticals Ltd.'s price crossed above 100Day SMA today

Glenmark Pharmaceuticals Ltd.

17 Nov 2025

2173.80

1.37%

Tough quarter led by GST shock and operational reset

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) delivered a miss on 2QFY26 earnings, adjusted for a one-time upfront payment received from Abbvie. The miss was largely driven by a severe impact on the domestic formulation (DF) business following the GST transition.

Glenmark Pharmaceuti.. has an average target of 2241.50 from 4 brokers.

Glenmark Pharmaceuticals Ltd.

09 Sep 2025

2173.80

1.37%